Immunic(IMUX) - 2024 Q2 - Quarterly Results

Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update – Jason Tardio, Experienced Multiple Sclerosis Drug Commercialization Executive, Formerly with Novartis and Biogen, Appointed Chief Operating Of icer and President – – Strengthened Board of Directors with Appointment of Simona Skerjanec, Senior Pharmaceutical Executive and Thought Leader in Brain Health – – Ongoing, Twin Phase 3 ENSURE Trials in Relapsing Multiple Sclerosis and Phase 2 CALLIPER Trial in Progressive Mul ...